Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis

Lirussi, Flavio; Mastropasqua, E; Orando, Serena; Orlando, Rocco

doi:10.1002/14651858.cd005165

Cited by 25 publications

(32 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also uncertain is the role of prebiotics or probiotics as potential treatments for NASH. 77,78 Such agents are intriguing because they are generally safe and relatively inexpensive and might correct obesity-related alterations in the intestinal microbiome that may contribute to obesity, insulin resistance, and hepatic inflammation. 79 Caspase inhibitors are also being considered as possible treatments for NASH 80 to reduce hepatocyte apoptosis (which is increased in NASH) 81 back toward more normal levels.…”

Section: Targeted Pharmacologic Treatments For Obesity-related Liver mentioning

confidence: 99%

Hepatic Complications of Obesity

Diehl

2010

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Section: Targeted Pharmacologic Treatments For Obesity-related Liver mentioning

confidence: 99%

Hepatic Complications of Obesity

Diehl

2010

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

“…In patients with liver cirrhosis, probiotics have been shown to decrease hepatic encephalopathy [125,126], improve liver biochemistry [127] and decrease the rate of infection after liver transplantation [128]. Several meta-analyses have already supported the benefit of probiotics in preventing infection in the general hospital population [129][130][131]; however, the exact mechanism is still largely speculative.…”

Section: Probioticsmentioning

confidence: 99%

Störungen des angeborenen Immunsystems bei akuten und chronischen Lebererkrankungen

Leber

Mayrhauser

Rybczynski

et al. 2009

Wien Klin Wochenschr

View full text Add to dashboard Cite

Liver cirrhosis is a common disease causing great public-health concern because of the frequent complications requiring hospital care. Acute liver failure is also prone to several complications but is rare. One of the main complications for both acute and chronic liver diseases is infection, which regularly causes decompensation of cirrhosis, possibly leading to organ failure and death. This review focuses on innate immune function in cirrhosis, acute-on-chronic liver failure and acute liver failure. The known defects of Kupffer cells, neutrophils and monocytes are discussed, together with the pathophysiological importance of gut permeability, portal hypertension and intrinsic cellular defects, and the role of endotoxin, albumin, lipoproteins and toll-like receptors. Based on these different pathomechanisms, the available information on therapeutic strategies is presented. Antibiotic and probiotic treatment, nutritional support, artificial liver support, and experimental strategies such as inhibition of toll-like receptors and use of albumin and colony-stimulating factors are highlighted.

show abstract

“…In patients with liver cirrhosis, probiotics have been shown to decrease hepatic encephalopathy [13,14], improve liver biochemistry [15] and decrease infection rates post liver transplantation [16]. Several meta-analyses have supported the benefit of probiotics in preventing infections in the general hospital population [17][18][19], however, the exact mechanism remains largely speculative.…”

Section: Introductionmentioning

confidence: 99%